Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Quintiles Acquires Expression Analysis

Published: Tuesday, August 14, 2012
Last Updated: Tuesday, August 14, 2012
Bookmark and Share
Acquisition of premier provider of genomics services to advance personalized medicine.

To help biopharmaceutical companies dramatically improve drug development productivity and deliver greater value, Quintiles has announced the acquisition of Expression Analysis, Inc. (EA), a premier provider of genomics testing and analysis to biopharma, academic, government and non-profit customers.

Terms of the transaction were not disclosed. This is the latest in a series of acquisitions and alliances designed to help Quintiles customers leverage the power of genomics to better understand diseases; develop diagnostic tools; and deliver safer, more effective therapies based on the genetic makeup of the disease and the patient.

The addition of EA’s Genomic Know-How® to Quintiles is another step forward in our efforts to bring personalized medicine into mainstream drug development, said Thomas Wollman, Senior Vice President, Quintiles Global Laboratories.

Its expertise in genetic sequencing and advanced bioinformatics is essential to understanding diseases and drugs at the molecular level. That’s a huge step in creating more value across the healthcare spectrum.

EA has about 77 employees, most based in its offices near Research Triangle Park.

Steve McPhail, EA President and Chief Executive Officer, said: The combination of Quintiles Global Laboratories and EA genomic technology excellence will facilitate worldwide access to resources and expertise to drive improvements in the diagnosis, treatment and management of complex disease. EA can now play a global role in helping biopharma succeed in the New Health. This is the right move for our company and our employees. Our mission perfectly fits Quintiles strategy to use genomic data and advanced informatics to yield actionable insights and more effective personalized treatments.

EA provides whole genome to focused-set gene expression and genotyping assays, along with next-generation sequencing services, sequence enrichment technologies and bioinformatics support.

It offers a broad range of services across multiple platforms. Its quality system follows CLSI guidelines and its CLIA-registered laboratory supports GLP compliance.

Quintiles Global Laboratories supports trials worldwide with wholly owned facilities in the U.S., Europe, South Africa, India, China, Singapore and Japan, and a tightly coordinated network of affiliate laboratories in Argentina and Brazil.

All Quintiles laboratories operate with uniform instrumentation and standard operating procedures, delivering high quality, harmonized data.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Quintiles and Kaiser Permanente Announce Alliance to Accelerate Drug Development
Quintiles and SCPMG to work together closely to enhance the productivity and quality of clinical research offered at the SCPMG site.
Friday, May 21, 2010
Scientific News
Breast Cancer Drug Hope
A drug for breast cancer that is more effective than existing medicines may be a step closer thanks to new research.
A New Platform for Discovering Antibiotics
Harvard chemists hope to shorten time, difficulty in measuring their effectiveness, potential.
Non-Toxic Approach to Treating Variety of Cancers
A team of researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine recently discovered a novel, non-toxic approach to treating a wide variety of cancers.
Making Injectable Medicine Safer
Researchers remove excess additives from drugs, which could reduce the odds of serious allergic reactions and other side effects.
Turning Skin Cells into Heart, Brain Cells
In a major breakthrough, scientists at the Gladstone Institutes transformed skin cells into heart cells and brain cells using a combination of chemicals.
Experimental Drug Cancels Effect from Key Intellectual Disability Gene
A University of Wisconsin—Madison researcher who studies the most common genetic intellectual disability has used an experimental drug to reverse — in mice — damage from the mutation that causes the syndrome.
Doubling Down on Dengue
HMS researchers have discovered two ways a compound blocks dengue virus.
Reprogramming Scorpion Venom
‘Twist of nature’ neutralizes toxin.
Tailoring a Suit for Tumor-Penetrating Cancer Meds
For more than a decade, biomedical researchers have been looking for better ways to deliver cancer-killing medication directly to tumors in the body.
Resurrecting an Abandoned Drug
Previously discarded drug shows promise in helping human cells in a lab dish fight off two different viruses.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!